Hepatitis C virus (HCV) infection is a global
|
|
- Gervais Lynch
- 5 years ago
- Views:
Transcription
1 VIRAL HEPATITIS Genetic Variation in the Interleukin-28B Gene Is Not Associated With Fibrosis Progression in Patients With Chronic Hepatitis C and Known Date of Infection Francesco Marabita, 1 * Alessio Aghemo, 2 * Stella De Nicola, 2 Maria G. Rumi, 3 Cristina Cheroni, 1 Rossana Scavelli, 1 Marco Crimi, 1 Roberta Soffredini, 2 Sergio Abrignani, 1 Raffaele De Francesco, 1 and Massimo Colombo 2 Polymorphisms in the interleukin-28b (IL28B) region are associated with spontaneous and treatment-induced viral clearance in hepatitis C virus (HCV) infection. Nevertheless, it is unknown whether genetic variation at the IL28B locus influences the natural history of chronic HCV infection. Thus, we asked whether an association between IL28B polymorphisms and liver fibrosis progression existed. We studied 247 consecutive patients with chronic HCV, an accurate estimate of the date of infection, and a liver biopsy performed before any treatment. No patient had a history of alcohol abuse or coinfection with other viruses. We assessed the role of rs and rs polymorphisms and the effect of host and environmental factors on fibrosis progression. Blood transfusion (75%) was the main modality of infection. Median age at infection was 21 years, and median interval between infection and liver biopsy was 25 years. One hundred twenty-nine patients (52%) were infected by HCV-1, 74 (30%) by HCV-2, 34 (14%) by HCV-3, and 10 (4%) by HCV- 4. Bridging fibrosis/cirrhosis (Ishak 4) was detected in 24% of patients. Age at infection had a marked effect on fibrosis progression by both a linear model and Cox proportionalhazard regression (P < 2E-16). A 12.1% increase in the hazard of advanced fibrosis was estimated for each additional year at infection, suggesting that this was the major explanatory variable in this cohort. Male gender (P < 0.05), HCV genotype 3 (P < 0.001) and steatosis (P < 0.05) were also associated with faster fibrosis progression. Conversely, the two IL28B polymorphisms had no impact on fibrosis progression. Conclusion: In HCV patients with a known date of infection, IL28B genotype was not associated with fibrosis progression rate or with the risk of developing advanced liver fibrosis. (HEPATOLOGY 2011;54: ) Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; CI, confidence interval; EDTA, ethylenediaminetetraacetic acid; FPR, fibrosis progression rate; gdna, genomic DNA; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN-c, interferon gamma; IL28B, interleukin-28b; PEG-IFN/RBV, pegylated interferon plus ribavirin; SNPs, single-nucleotide polymorphisms; SVR, sustained virologic response; TGF-b, transforming growth factor beta; TNFa, tumor necrosis factor alpha. From the 1 Istituto Nazionale Genetica Molecolare, Milano, Italy; 2 A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Milano, Università degli Studi di Milano, Milano, Italy; and 3 Division of Hepatology, Ospedale San Giuseppe, Università degli Studi di Milano, Milano, Italy. Received February 18, 2011; accepted June 7, *These authors contributed equally to the manuscript. Address reprint requests to: Raffaele De Francesco, Ph.D., Istituto Nazionale Genetica Molecolare Milano, Via Francesco Sforza 35, Milan 20122, Italy. defrancesco@ingm.it; fax: þ Copyright VC 2011 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI /hep Potential conflict of interest: Dr. Rumi received grants from Roche, Janssen, and Gilead. Dr. Colombo advises and received grants from Roche, Merck, Gilead, Bayers, and Bristol-Myers Squibb. He also advises Tibotec. Additional Supporting Information may be found in the online version of this article. Hepatitis C virus (HCV) infection is a global health care burden, with roughly 1%-2% of the European and U.S. populations being chronic carriers of the virus. Although HCV can lead to extrahepatic manifestations in a minority of patients, the prognosis of the disease is directly linked to the restless accumulation of fibrotic tissue in the liver, which, ultimately, alters the liver architecture and its vascularization, leading to the development of cirrhosis and its sequelae. Among the many factors known to substantially contribute to this process by determining a more rapid progressive course of the disease, emphasis has been put on a variety of environmental components, such as alcohol abuse and viral coinfections, and host risk factors, such as insulin resistance, obesity, and immunity. 1,2 More recently, HCV genotype 3 has been shown to be associated with accelerated fibrosis progression, compared to non-3 genotypes. 3,4 Although 1127
2 1128 MARABITA ET AL. HEPATOLOGY, October 2011 these factors do explain part of the extreme variability seen in fibrosis progression among HCV-infected patients, they do not completely account for these differences. Thus, the prediction of the rate of disease progression at an individual level is still quite inaccurate, often making impossible the selection of patients for anti-hcv treatment on the basis of the risk to progress to the advanced stages of hepatitis. Some evidences exist on the role of host genetics in modifying disease progression, because several single-nucleotide polymorphisms (SNPs) located in various genes, including interferon gamma (IFN-c), tumor necrosis factor alpha (TNF-a), and transforming growth factor beta (TGF-b), among others, have been associated with progression of liver fibrosis. 2 A recent article supported these findings, providing evidence that a seven- SNP signature was associated with fibrosis progression in a large cohort of HCV-infected patients in Italy. 5 Among the SNPs identified to play a major role in HCV infection, those located in the IL28B region on chromosome 19 have been strongly associated with spontaneous and treatment-induced viral clearance in patients of different ethnicity Thus, patients with the T/T and C/T genotype at the rs SNP (nonresponder genotype) have been shown to exhibit a slower viral decline after pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, with the sustained virologic response (SVR) rates being significantly lower, compared to patients with the favorable C/C genotype. 11 Although this discovery has radically changed the landscape of antiviral treatment for HCV patients, providing insights into the mechanisms of IFN hyporesponsiveness, the precise mechanisms behind this association still needs to be unraveled. In addition, whether there is a link between the clinical manifestation of chronic HCV infection and the patient IL28B genotype is still an open question. Here, we asked whether a correlation between IL28B SNPs and fibrosis progression exists. To test this hypothesis, we studied 247 consecutive patients with a known date of HCV infection, whose liver fibrosis was staged by a percutaneous liver biopsy. We studied the effect of host and external factors on both fibrosis progression rate and advanced fibrosis stage. Patients and Methods Patients. A total of 247 participants with chronic HCV infection were included in this study. All participants were consecutively selected at the Center for Liver Disease at Maggiore Hospital (Milan, Italy). Inclusion criteria comprised the following: (1) HCV RNA serum positivity; (2) European descent; (3) an estimated date of HCV infection based on the first reported parenteral risk factor; (4) a diagnostic liver biopsy before antiviral treatment performed at least 4 years after the date of infection; and (5) no history of past or current alcohol use (>20g/day). Patients were excluded if they had any other cause of liver disease, including hepatitis B virus infection, human immunodeficiency virus (HIV) infection, Wilson s disease, hemochromatosis, or a1-antitrypsin deficiency. We also excluded patients with type 1 or 2 diabetes. Duration of disease was calculated by considering the time elapsed between the year of infection and the liver biopsy. Liver biopsies were evaluated by a single expert pathologist and scored using the Ishak system in separate reports for grading and staging. The score for staging ranged from 0 (no fibrosis) to 6 (cirrhosis). The study was approved by the Institutional Review Board of the Department of Internal Medicine at Maggiore Hospital. All patients gave their written informed consent to receive therapy and gave permission for use of their medical records. DNA Extraction and Genotyping. Genomic DNA (gdna) was extracted from 1 ml of ethylenediaminetetraacetic acid (EDTA) whole blood. Briefly, Gene- Catcher magnetic beads (Invitrogen, Carlsbad, CA) were used in a semiautomatic procedure on a FreedomEVO platform (Tecan, Männedorf, Switzerland). After final elution, gdna concentration and purity were evaluated and the sample was further processed if A260/A and A260/ For rs , genotype data were obtained from genome-wide profiling with the Human660W-Quad BeadChip (Illumina, San Diego, CA), after SNP calling with the default settings of Genome Studio software. Conversely, for rs , TaqMan SNP genotyping assays were run on a 7900HT real-time polymerase chain reaction instrument (Applied Biosystems, Carlsbad, CA), following the manufacturer s instruction. Statistical Analysis. To quantitatively describe disease outcome, a fibrosis progression rate (FPR) was calculated by taking the ratio between the Ishak score (staging value) and the disease duration (in years). This calculation assumes that no significant liver fibrosis was present at the time of infection. A generalized linear model was formulated and fitted to the data, specifying the IL28B SNP genotypes and the covariates as explanatory variables, namely age at infection, gender, HCV genotype, the presence of moderate to severe liver steatosis (grade 2-3), the presence of liver necroinflammatory lesions (histological grading 9), and the body-
3 HEPATOLOGY, Vol. 54, No. 4, 2011 MARABITA ET AL Table 1. Patient Characteristics, Stratified By HCV Genotype ALL HCV1 HCV2 HCV3 HCV4 Patients Males % % % % % Females % % % % % Median age at infection, years (range) 21 (0-59) 22 (0-59) 22 (0-56) 19 (0-42) 21 (15-33) Median age at biopsy, years (range) 47 (11-72) 48 (13-72) 50 (11-66) 43.5 (24-64) 41 (33-53) Median duration, years (range) 25 (4-53) 25 (6-53) 25.5 (5-52) 23 (4-43) 19.5 (9-28) Mean biopsy length, mm (SD) 26.3 (5.2) 26.5 (4.9) 25.6 (5.8) 26.8 (4.7) 24.7 (6.5) Fibrosis stage (Ishak) % 2 1.6% 0 0.0% 0 0.0% 0 0.0% % % % % % % % % % % % % % % % % % 5 6.8% 3 8.8% 0 0.0% % % 3 4.1% 1 2.9% 0 0.0% % % 2 2.7% % % Grading Minimal to mild (<9) % % % % % Moderate to severe (9) % % % 3 8.8% % Steatosis None to slight (0-1) % % % % % Moderate to severe (2-3) % % % % % Reported risk Blood transfusion % % % % % Intravenous drug use % % % % % Other 4 1.6% 1 0.8% 2 2.7% 1 2.9% 0 0.0% BMI (kg/m 2 ) Mean (SD) 25.3 (2.8) 25.3 (2.8) 25.5 (2.8) 25.0 (2.5) 25.9 (2.2) Abbreviations: HCV, hepatitis C virus; SD, standard deviation; BMI, body mass index. mass index (BMI). A log10 transformation of the FPR was employed to obtain linearity. For cases having an Ishak ¼ 0, the log10(fpr) was substituted with the lowest value observed. For SNP data, the minor allele was counted as follows: rs TT ¼ 0, TG ¼ 1, GG ¼ 2; rs CC ¼ 0, CT ¼ 1, TT ¼ 2. The model was checked through the regression diagnostic plots to verify normality, linearity of the data, and constant variance. The effect of the explanatory variables was considered significant if P < 0.05 and a final model was established with the significant terms only. Additionally, survival analysis was performed to model the time taken for advanced fibrosis to occur. Here, advanced fibrosis was defined if Ishak 4. A Cox proportional-hazards regression model was fitted, and the covariates were considered significant if P < The proportional hazard assumption was checked and a final model was proposed, considering the significant terms only. All statistical analyses were performed in R, 12 using the survival library for Cox regression. 13 Results Patient Characteristics. For the present analyses, 247 patients consecutively attending our center between September 2008 and March 2010 that fulfilled the strict selection criteria were selected. Patient characteristics are outlined in Table 1. The majority of the patients were infected with HCV genotype 1 (52%), although this study included subjects with HCV genotypes 1, 2, 3, and 4. Both males and females were well represented (52% males, 48% females). Median age at infection was 21 years, median disease duration was 25 years, and median age at biopsy was 47 years. Mean biopsy length was 26.3 mm. The FPR distribution resulted in being right-skewed, but approached a normal distribution after log10 transformation (see Supporting Information). The majority of the patients (87%) had minimal to mild histological activity (grade <9), whereas a minor fraction (13%) showed moderate to severe activity (grading 9). Moderate or severe steatosis (grade 2-3) was observed in 20% of the patients. Mean BMI was 25.3 kg/m 2. The main reported risk factors for HCV infection were blood transfusions (75%) and the use of intravenous drugs (23%), with mother-to-child, needlestick, or sexual transmission as the other reported risks. In this cohort, 29 patients were age 0 at infection. Only 1 of these patients acquired the infection vertically, whereas the others received a blood transfusion at birth. IL28B genotypes of patients with absent or mild fibrosis (Ishak <4) and patients with advanced fibrosis (Ishak 4) are shown in Table 2. Genotype frequencies
4 1130 MARABITA ET AL. HEPATOLOGY, October 2011 Table 2. IL28B Genotype Counts and Frequencies* rs rs TT GT GG P value b CC TC TT P valuey Absent to mild fibrosis (Ishak <4) 98 (0.52) 81 (0.43) 8 (0.04) (0.35) 95 (0.51) 27 (0.14) 0.48 Advanced fibrosis (Ishak 4) 33 (0.55) 25 (0.42) 2 (0.03) 23 (0.38) 32 (0.53) 5 (0.08) All patients 131 (0.53) 106 (0.43) 10 (0.04) 88 (0.36) 127 (0.51) 32 (0.13) *Genotypes counts (frequencies) are given. Fisher s exact test. Abbreviation: IL28B, interleukin-28b. did not differ significantly between the two groups, regardless of the analyzed SNP (rs or rs ). Moreover, SNP genotype frequencies did not deviate significantly from Hardy-Weinberg equilibrium expectation at a threshold of P ¼ The measured genotype frequencies are consistent to other published reports with HCV-infected patients. 6,7 Linear Model. To evaluate the contribution of genetic and nongenetic factors in the natural history of chronic HCV infection, we performed multiple analyses aimed at the definition of the individual contribution to fibrosis progression in the cohort of patients described above (see Patients and Methods). Here, we evaluated whether the genotype of rs and rs polymorphisms could influence fibrosis progression in the liver of HCV-infected patients. In a first analysis framework, we modeled the dependence of log10(fpr) on a linear combination of IL28B SNP genotypes along with different variables already reported to influence fibrosis progression. These were age at infection, patient gender, HCV genotype, the presence of steatosis, BMI, and inflammatory grading. An interaction term was specified between steatosis and viral genotype, to reflect that the effect of steatosis on fibrosis progression may be specific for different genotypes. The final model was chosen on the basis of the minimum Akaike information criterion. The results summarized in Table 3 show that age at infection was the variable most strongly and positively associated with fibrosis progression (P < 2E-16). Male gender (P ¼ 0.012), HCV genotype 3 (P ¼ 7.19E- 04), and the presence of steatosis (P ¼ 0.012) also resulted in being significantly associated with an accelerated rate of fibrosis progression. Importantly, the two IL28B SNPs had no significant effect on the outcome, and thus they were removed from the final model (Table 3). It is worth pointing out that HCV genotype 2 was associated with a slower rate of fibrosis progression (P ¼ 0.034), as also suggested in a previous study. 14 Single-term deletion analysis further confirmed the role of these explanatory variables. Figure 1 shows the remarkable effect of age at infection on rate of fibrosis progression. In contrast, no effect could be attributable to the host IL28B genotype. Notably, no impact on FPR was found, also assuming a dominant model of inheritance for the alleles, rs G or rs T, previously associated with treatment failure (data not shown). On the contrary, when these two SNPs were tested for association with therapy outcome, using data from 91 patients with HCV genotype 1 and available treatment information, the effect was readily detectable (see Supporting Information). Actually, rs genotypes CT and TT versus CC resulted in being associated with treatment failure (P < 0.01, odds ratio ¼ 3.6, 95% CI ¼ ), in agreement with previous reports. Finally, we evaluated the role of explanatory variables, excluding individuals that acquired the infection at birth, to exclude possible confounding factors originating from the inclusion of a group of patients that acquired the infection in the setting of an immature immune system. In this subgroup of patients, we obtained the same estimates of the parameters and confirmed the lack of any effect by the two IL28B polymorphisms and the significant role of the nongenetic factors (Supporting Table 1). In summary, the model outlined in Table 3 which includes patient gender, age at infection, viral genotype, and steatosis explained an estimated 34% of the phenotypic variability, showing that patient age at infection has a major, highly significant role on fibrosis Table 3. Variables Significantly Affecting the Fibrosis Progression According to Linear Model Estimate 95% CI P value Age at infection <2E-16 Male gender HCV2* 0.084* to 0.007* 0.034* HCV E-04 Steatosis (grade 2-3) Estimate ¼ effect size on log fibrosis progression rate; 95% CI ¼ 95% confidence interval for the estimate. Hepatitis C virus (HCV) genotype 1 was considered the reference level. *Parameters estimated from the model without the interaction term between HCV genotype and steatosis.
5 HEPATOLOGY, Vol. 54, No. 4, 2011 MARABITA ET AL Fig. 1. Effect of age at infection and IL28B genotype on fibrosis progression. (A) Scatterplot between age at infection (years) and fibrosis progression (log10 FPR) shows that patients with younger age at infection have slower disease progression. (B, C) Conversely, no association was found between IL28B rs or rs genotype and disease progression. Boxplots depict median value (bold lines), interquartile range (boxes), minimum and maximum values (whiskers), and outliers (circles). progression, in agreement with other reports The estimated effect on fibrosis progression of each additional year at infection was a 2.8% (95% CI ¼ 2.2%- 3.4%) increase in FPR. Cox Proportional-Hazard Model. When using the FPR, we made the assumption of a linear fibrosis progression over time. To avoid biases imposed by the above assumption, we decided to use an alternative analysis approach. Thus, we also used a proportionalhazard survival model to analyze the relationship between the above-mentioned explanatory factors and the time it takes to develop bridging fibrosis or cirrhosis (Ishak 4). In agreement with the linear model, the significant variables found with this model were age at infection (P ¼ 1.26E-13), male gender (P ¼ 0.018), HCV genotype 3 (P ¼ 0.004), and steatosis (P ¼ 0.003), whereas the two IL28B polymorphisms had no effect on the estimated hazard of developing advanced fibrosis (Table 4; Fig. 2). From the estimates of the coefficients, we can derive the effect on the hazard. Thus, holding the other covariates constant, each Table 4. Variables Significantly Associated to the Hazard of Advanced Fibrosis According to the Cox Proportional-Hazard Model Estimate Effect 5 e estimate 95% CI P value Age at infection E-13 Male gender HCV2* 1.035* 0.355* * 0.005* HCV Steatosis (grade 2-3) Estimate ¼ effect size on the log-hazard; Effect ¼ e estimate, or multiplicative effect on the hazard; 95% confidence interval for the effect; hepatitis C virus (HCV) genotype 1 was considered the reference level. *Parameters estimated from the model without the interaction term between HCV genotype and steatosis. additional year at infection produces a highly significant increase of the hazard of advanced fibrosis by a factor of (95% confidence interval [CI] ¼ ) or 12.1%. This effect is clearly evident when plotting the estimated survival functions for three representative infection times (0, 20, or 40 years of age, respectively; Fig. 2). Indeed, the three survival functions are well separated and their corresponding CIs do not overlap. Conversely, the corresponding estimated survival functions by IL28B genotype are clearly overlapping, underscoring the lack of any effect of these variables. Furthermore, the effect of HCV genotype, gender, and steatosis were also significant, but their estimates had wider CIs (Table 4). Discussion It is now well established that genetic variations in the region of the IL28B gene on chromosome 19, coding for IFN-k3, are strongly associated with the achievement of treatment-induced or spontaneous viral clearance in individuals infected with HCV. 11 In particular, numerous studies have shown that individuals with the C/C genotype at the rs SNP (i.e., protective or responder genotype) have higher rates of rapid, sustained virological response to treatment with the current standard of care (i.e. PEG-IFN/RBV), compared to those carrying the T allele (C/T and T/T genotypes). More recently, it has also been proposed that the poor response IL28B variants, in hepatitis C patients, are also associated with lower pretreatment low-density lipoprotein cholesterol levels, 17,18 hepatic steatosis, 18,19 and insulin resistance, 19 compared to the responder genotype. However, it is still unclear whether the genetic variation at the IL28B locus affects the severity and pace of the progression of liver
6 1132 MARABITA ET AL. HEPATOLOGY, October 2011 Fig. 2. Younger age at infection reduces the hazard of developing advanced fibrosis, whereas the IL28B genotype has no effect. (A) Estimate survival functions for Cox regression of time to advanced fibrosis on significant predictors, namely age at infection, gender, HCV genotype, and steatosis. The proportion of patients not having advanced fibrosis is shown as a function of disease duration in years. Three survival functions are estimated for three representative infection times (0, 20, or 40 years of age, respectively), fixing other covariates (HCV genotype ¼ 1, gender ¼ proportion of males, and steatosis ¼ proportion of individuals with moderate/severe steatosis in the cohort). Thin dashed lines represent 95% confidence envelopes. (B) Estimated survival functions by rs genotype. IL28B has no effect on the hazard of advanced fibrosis. Three survival functions are estimated for the three rs genotypes, fixing other covariates (HCV genotype ¼ 1, age at infection ¼ average value, gender ¼ proportion of males, and steatosis ¼ proportion of individuals with moderate/severe steatosis in the cohort). disease. Indeed, though some investigators found that the unfavorable rs T/T gene pattern was associated with worse liver fibrosis, others did not replicate this finding. Bitetto et al. 20 looked at the link between the IL28B rs SNP and fibrosis stage in 548 individuals with chronic HCV infection, and found that carriage of the T/T genotype (n ¼ 78) was associated with a higher staging score (Ishak 3 or 4), after adjusting for age, sex, BMI, alcohol intake, and diabetes mellitus, compared to the other two genotypes (n ¼ 470; P < 0.02). In contrast, a smaller study from a different group performed on 129 patients with HCV genotype 1 failed to find a similar association. 21 Thompson et al. exploited the large patient population enrolled in the IDEAL study to investigate the relationship between IL28B polymorphisms and liver disease severity. 22,23 In the first analysis, 1,329 patients were genotyped and the researchers observed no relationship between IL28B rs and advanced fibrosis (METAVIR stage F3-F4). In the second analysis, however, the researchers did see a link between rs genotype, alanine aminotransferase (ALT) levels, and necroinflammatory activity, with C/C patients having higher pretreatment ALT values and more often moderate-to-severe (METAVIR stage A2-A3) necroinflammatory activity. Because elevated ALT and high histological grading are known to be associated with a faster fibrosis progression in patients with chronic hepatitis C, in principle, these findings could support a role of the IL28B polymorphisms as a determinant of disease severity. 24 However, a limitation of all these studies is represented by the fact that the association between IL28B genetic variants and the presence of advanced fibrosis or cirrhosis was investigated without taking into consideration the time elapsed from the acquisition of the infection. For this reason, we decided to assess the potential association between IL28B polymorphisms and the rate of progression of liver fibrosis in a cohort of well-characterized patients for whom an accurate estimation of the date of infection could be obtained. Additionally, in the attempt to minimize the role of confounding factors in the interpretation of our data, we restricted our analysis to Caucasian patients only and excluded also patients with diabetes or those reporting past or current regular alcohol consumption. Using such strict inclusion criteria, we found that the host genetic background at the IL28B locus is not associated with the risk of developing advanced fibrosis. Conversely, we show that other factors have a strong impact on disease outcome, being strongly associated with fibrosis progression, as previously reported. 1,2 In a first effort to correlate disease progression with host and external variables, we modeled the fibrosis progression rate as a continuous outcome, considering the ratio between fibrosis level and disease duration. Although this approach might have been biased by the assumption that the rate of progression to cirrhosis remains constant over time, 15 this method represents a way to consider the duration of the chronic disease within the model, instead of a simple split of the population in two groups on the basis of fibrosis score
7 HEPATOLOGY, Vol. 54, No. 4, 2011 MARABITA ET AL alone. In this model, we observed no effect of IL28B genotypes on fibrosis progression, whereas we confirm the well-established role of a number of other factors. Indeed, we detected a strong effect of age at infection on rate of disease progression, namely a 2.8% increase in the speed of disease progression for each additional year. This significant effect is manifested by the fact that patients infected perinatally have very slow progression of liver fibrosis. For those patients, mean progression is FPR units, corresponding approximately to an increase of 2 Ishak points in 40 years, similarly to other reports. 25,26 Additionally, male gender and HCV genotype 3 resulted in being significantly associated with fast progression, compared to female gender and HCV genotype 1, respectively. Although there is general agreement on the faster disease observed in males, the role of HCV genotype has remained controversial for a long time. According to our data, patients with HCV genotype 3 have a faster disease progression, confirming other recent studies. 3,4 However, whether this association is directly mediated by the virus through the increased steatosis observed in patients with HCV genotype 3 or is a consequence of other external factors is still debated. 27,28 In our models, we included an interaction term between viral genotype and steatosis to account for the reasonable different influence of steatosis according to HCV genotype. Indeed, correcting for steatosis, we still detected an effect for the HCV 3 genotype, suggesting that the faster fibrosis progression observed in genotype 3 patients appears to be not completely explained by the presence of steatosis. Because patients with HCV genotype 3 infection acquired the virus, in most cases, during drug abuse in the 1970s-1980s, the confounding role of past alcohol use/abuse, even for a limited time period, cannot be completely ruled out as a relevant factor. Although, in our study, we did exclude patients reporting significant alcohol use in the past (>20g/day), we cannot completely rule out that our patients underreported alcohol consumption, especially if limited in time. Interestingly, viral genotype 2 was more weakly, but significantly, associated with a slower progression of liver fibrotic disease in our cohort. The same observation was described in a landmark article, where Poynard et al. 14 reported that patients infected with genotype 2 had a slower rate of fibrosis progression relative to genotypes 1a or 1b, although the differences were not significant, presumably owing to the small number of patients with available genotypes. To confirm the results of our analyses, in spite of the limitation of the model assumptions, we also used a Cox proportional-hazard regression to directly estimate the hazard of developing advanced fibrosis as a function of host and external factors. This analysis conveniently outputs the effect of the variables on the hazard, providing useful insight on the natural history of HCV infection. In this model, age at infection was the major contributor to the hazard of advanced fibrosis, with male gender, HCV genotype 3, and steatosis being significantly, but more weakly, associated with liver disease progression. Once again, the IL28B polymorphisms had no influence on the hazard of developing advanced fibrosis. We do acknowledge that our study was not completely free of limitations, as we could not properly evaluate the influence of known accelerators of fibrosis progression, such as being overweight and past alcohol abuse. 29 However, with respect to the influence of IL28B polymorphisms on disease progression, it seems unlikely that these factors might have been skewed toward one genotype to provide a significant bias. Moreover, assessing liver fibrosis through percutaneous biopsy does have some limitations, including sampling error bias, which accounts for differences in staging score of at least 1 point in up to 20% of cases when liver biopsies are performed in both lobes. 30 Furthermore, a misdiagnosis of cirrhosis is seen in up to 30% of specimens. 31 Nevertheless, despite all these caveats, liver biopsy is still considered the standard, if not the gold standard, for fibrosis staging. 32 The correct identification of the time of infection is a critical point in determining the role of any predictor of disease progression in an acquired disease, such as chronic hepatitis C. Our study, from this point of view, was particularly solid, because, in most of our patients, the infection was acquired during a datable event, such as multiple blood transfusions or intravenous drug abuse. For this reason, we believe that our study provides important insights into the natural history of HCV infection and, specifically, into fibrosis progression and their relationship with host and external factors. In conclusion, we show that the IL28B genotype does not have an effect on the risk of developing advanced fibrosis, whereas age at infection, male gender, and infection with HCV genotype 3 are confirmed to accelerate disease progression. This finding has important implications, as it opens additional questions on the role of host genetic factors in the modulation of disease progression. Further studies of the host genetic determinants associated with risk of liver disease progression in hepatitis C should represent a high priority of the scientific community, with the aim of both allowing a better understanding of disease pathogenesis and guiding an improved patient-selection process for eligibility to antiviral therapy.
8 1134 MARABITA ET AL. HEPATOLOGY, October 2011 Acknowledgment: The authors thank Prof. Mario Comelli for his special statistical support and help in writing the manuscript for this article. References 1. Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002;36: S35-S Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134: Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51: De Nicola S, Aghemo A, Rumi MG, Colombo M. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 2009;51: Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. HEPATOLOGY 2009;50: Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461: Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41: Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41: Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138: , 1345e1-e Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461: Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB. Hepatitis C pharmacogenetics: State of the art in HEPATO- LOGY 2011;53: R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; Available at: Terry Therneau and original R port by Thomas Lumley. Survival: survival analysis, including penalised likelihood. R package version Available at: Accessed on February 18, Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, META- VIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349: Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34: Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, et al., HENCORE collaboration. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003;52: Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. HEPATOLOGY 2010;51: IL28B genetic polymorphism has genome wide significant associations with serum low density lipoprotein levels and hepatic steatosis in patients with genotype 1 chronic hepatitis C. HEPATOLOGY 2010; 52(Suppl 1):439A. 19. Stättermayer A, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Hofer H, et al. Influence of IL28B-genotype on insulin resistance in treatment-naïve patients with chronic hepatitis C [Abstract]. HEPATOLOGY 2010; 52(Suppl 1):1224A. 20. Bitetto D, Fabris C, Fornasiere E, Fumolo E, Cussigh A, Bignulin S, et al. IL28B rs C>T polymorphism affects the evolution of chronic hepatitis C [Abstract]. HEPATOLOGY 2010;52(Suppl 1):438A. 21. Del Campo JA, Maraver Zamora M, Ramírez-Lorca R, Pardo-Yules B, Sáez ME, Real LM. IL28B polymorphism predicts sustained virological response in hepatitis C but is not associated with fibrosis or viral load [Abstract]. HEPATOLOGY 2010;52(Suppl 1):748A. 22. Thompson AJ, Clark PJ, Fellay J, Muir AJ, Tillmann HL, Patel K, et al. IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the ideal study [Abstract]. HEPATOLOGY 2010;52(Suppl 1):437A. 23. Thompson AJ, Clark PJ, Zhu M, Zhu Q, Ge D, Sulkowski MS, et al. Genome-wide association study identifies IL28B polymorphism to be associated with baseline alt and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study [Abstract]. HEPATOLOGY 2010;52(Suppl 1):1220A. 24. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. HEPATOLOGY 2004;39: Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection. J Infect Dis 2000;181: Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male P-J, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004;53: Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130: Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. HEPATOLOGY 2005;41: Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterology 2002;97: Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008;134: Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009;50:1-3.
The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationDisclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR
29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,
More informationHepatitis C virus (HCV) infection is estimated
Interleukin-28B Genetic Variants and Hepatitis Virus Infection by Different Viral Genotypes Marco Antonio Montes-Cano, 1 José Raúl García-Lozano, 1 Cristina Abad-Molina, 1 Manuel Romero-Gómez, 2 Natalia
More informationGenetic Determinants in HCV
Genetic Determinants in HCV Lynn E. Taylor, MD Assistant Professor of Medicine Warren Alpert Medical School of Brown University The Miriam Hospital Providence, RI April 27, 2011 Disclosure My presentation
More informationASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?
ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? DO WE NEED LIVER BIOPSY? Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA POTENTIAL
More informationInterferon Lambda-3 rs Variants and Response to Pegylated Interferon in Chronic Hepatitis-C Genotype-3
ORIGINAL ARTICLE Interferon Lambda-3 rs12979860 Variants and Response to Pegylated Interferon in Chronic Hepatitis-C Genotype-3 ABSTRACT Objective: To assess the role of single nucleotide polymorphisms
More informationROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV
ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant Professor Department of Medicine Queen Mary Hospital The University of Hong Kong HCV GENOTYPES:
More informationOver the last 2 years exciting novel pharmacogenetic
Clinical Utility of Interleukin-28B Testing in Patients With Genotype 1 Michelle Lai and Nezam H. Afdhal See Editorial on Page 5 Over the last 2 years exciting novel pharmacogenetic data have emerged on
More informationCriteria Grid Hepatitis C Research Studies, Tools, and Surveillance Systems. Part A. Basic Science Clinical Science Public Health/Epidemiology
Criteria Grid Hepatitis C Research Studies, Tools, and Surveillance Systems Best Practice/Intervention: Date of Review: March 23, 2015 Reviewer(s): Christine Hu Category: Shi KQ. et al. (2012) Interleukin-28B
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationCLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2010;138:2307 2314 Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin JEANETTE J. MCCARTHY,* JOSEPHINE H. LI,* ALEXANDER
More informationPersonalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2
Monotematica AISF 213 Personalizzazione della Cura in Epatologia Pisa, 17-19 Ottobre 213 Epatite Cronica C: Pazienti con Genotipo 2 Maria Grazia Rumi U.O. Epatologia, Ospedale San Giuseppe Università degli
More informationAntiviral therapy guidelines for the general population
Discussion 10 Chapter 10 Hepatitis C a worldwide problem More than 170 million people worldwide suffer from chronic hepatitis C. Its prevalence is 2% in industrialized countries. 1 Approximately 20% of
More informationSupplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC
Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT
More informationPNPLA3 rs Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis
Gut and Liver, Vol., No. 3, May 016, pp. 456-463 ORiginal Article PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationSteatosi epatica ed HCV
Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationDetection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationL iver steatosis is a frequent histological finding in patients
420 LIVER Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis L Castéra, C Hézode,
More informationHepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...
Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN
More informationCHRONIC HCV TREATMENT: In Special Populations.
CHRONIC HCV TREATMENT: In Special Populations. By Taher EL-ZANATY Prof. of Internal Medicine CAIRO UNIVERSITY Introduction: HCV is the major cause of chronic hepatitis in Egypt. Its end stage is liver
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationPersistent infection with the hepatitis B virus
IL28B Polymorphisms Predict Interferon-Related Hepatitis B Surface Antigen Seroclearance in Genotype D Hepatitis B e Antigen Negative Patients With Chronic Hepatitis B Pietro Lampertico, 1 Mauro Vigano,
More informationPharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients
1 Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients Evaldo Stanislau Affonso de Araújo 1*&, Harel Dahari 2*$, Scott J Cotler 2, Thomas
More informationManagement of Incidental Hepatitis C Virus Infection
The new england journal of medicine Clinical Decisions Interactive at nejm.org Management of Incidental Hepatitis C Virus Infection This interactive feature addresses the diagnosis or management of a clinical
More informationT he hepatitis C virus (HCV) is a major cause of chronic
1638 VIRAL HEPATITIS Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C T Asselah, N Boyer, M-C Guimont, D Cazals-Hatem, F Tubach, K
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More information1. Introduction Milano, Italy 4 Istituto Nazionale Genetica Molecolare Milano (INGM), Milano, Italy
BioMed Research International Volume 2013, Article ID 580796, 6 pages http://dx.doi.org/10.1155/2013/580796 Clinical Study Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationChronic hepatitis B affects more than 350 million
GASTROENTEROLOGY 2012;142:513 520 Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B MILAN J. SONNEVELD,* VINCENT W. S. WONG, ANDREA M.
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationA meta-analysis of the association between IL28B polymorphisms and infection susceptibility of hepatitis B virus in Asian population
Chen et al. BMC Gastroenterology (2015) 15:58 DOI 10.1186/s12876-015-0286-2 RESEARCH ARTICLE Open Access A meta-analysis of the association between IL28B polymorphisms and infection susceptibility of hepatitis
More informationChronic infection with hepatitis C virus (HCV)
VIRAL HEPATITIS Inosine Triphosphatase Genetic Variants are Protective Against Anemia During Antiviral Therapy for HCV2/3 But Do Not Decrease Dose Reductions of RBV Or Increase SVR Alexander J. Thompson,
More informationThe treatment of choice for chronic hepatitis C is
Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationCase report Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis
Antiviral Therapy 04; 9:57 5 (doi:.85/imp684) Case report Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis Stella De Nicola, Alessio Aghemo *, Maria Rosaria Campise,
More informationNIH Public Access Author Manuscript Dig Dis Sci. Author manuscript; available in PMC 2012 December 11.
NIH Public Access Author Manuscript Published in final edited form as: Dig Dis Sci. 2012 August ; 57(8): 2213 2221. doi:10.1007/s10620-012-2171-y. The Association of Genetic Variants with Hepatic Steatosis
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationGenetics and hepatitis C: It s good to be CC
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will recognize the importance of the IL28B polymorphism and its implications in treating hepatitis C JOSE MARI PARUNGAO, MD Department of Gastroenterology,
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationThe Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (10), Page
The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (10), Page 7842-7849 Comparison between clinical and biochemical versus interleukin 28B as a predictive factor of virological response to
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHCV RNA profiles among chronic HIV/HCV coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in 9 individuals
HCV RNA profiles among chronic HIV/HCV coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in 9 individuals Daniel GRINT 1,2, Ellen TEDALDI 3, Lars PETERS 4, Amanda MOCROFT 1, Brian
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationEPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE
EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE E. Angeli, A. Mainini, C. Atzori, G. Gubertini and G. Rizzardini II Dept. Infectious
More informationOriginal article Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV
Antiviral Therapy 2016; 21:605 609 (doi: 10.3851/IMP3066) Original article Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV Edward J Gane 1,2 *, Robert H Hyland 3, Di An 3, Evguenia
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationINHSU th International Symposium on Hepatitis Care In Substance Users
INHSU 2015 4 th International Symposium on Hepatitis Care In Substance Users Sydney, 7 October 2015 Non-invasive liver fibrosis assessment: Opportunities for enhanced liver disease assessment and treatment
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationEffects of IL28B rs CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11:311 317 Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C SALVATORE
More informationReview Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?
Antiviral Therapy 2012; 17:1163 1170 (doi: 10.3851/IMP2427) Review Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Golo Ahlenstiel 1, David R Booth 2, Jacob George
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:688 693 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationOriginal article The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype
Antiviral Therapy 14:577 584 Original article The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype Alessio Aghemo 1, Maria
More informationHepatitis C wi w t i h Ju J dy y W y W a y t a t t
Hepatitis C with Judy Wyatt Hepatitis C and the histopathologist Pre-2006 biopsy based treatment of moderate-severe chronic hepatitis Now biopsy for: Watchful waiting, to confirm mild disease? Cirrhosis
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationLaboratory and Clinical Diagnosis of HCV Infection
Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More informationAccepted Manuscript. S (16)30397-X Reference: JHEPAT To appear in: Journal of Hepatology
Accepted Manuscript High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis Helder Cardoso, Ana Maria Vale, Susana Rodrigues,
More informationJPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print. Durability of Response in Children Treated with Pegylated Interferon
JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print DOI : 10.1097/MPG.0000000000000929 Durability of Response in Children Treated with Pegylated Interferon alfa-2a +/- Ribavirin
More informationCLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2010;138:108 115 Randomized Study of Peginterferon- 2a Plus Ribavirin vs Peginterferon- 2b Plus Ribavirin in Chronic Hepatitis C MARIA GRAZIA RUMI,* ALESSIO AGHEMO,* GIAN MARIA PRATI,*
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationLa sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV
WORKSHOP HCV: la guarigione e il parallelismo tra risposta virologica sostenuta e outcome clinico Milano, 25 Ottobre 2018 Ospedale San Raffaele IRCCS - Sede Turro La sindrome metabolica e il suo impatto
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationSupplementary Figure 1 Forest plots of genetic variants in GDM with all included studies. (A) IGF2BP2
Supplementary Figure 1 Forest plots of genetic variants in GDM with all included studies. (A) IGF2BP2 rs4402960, (B) MTNR1B rs10830963, (C) TCF7L2 rs7903146, (D) IRS1 rs1801278, (E) PPARG rs1801282, (F)
More informationClinical Infectious Diseases Advance Access published September 3, 2014
Clinical Infectious Diseases Advance Access published September 3, 2014 1 Acute hepatitis C virus infection in HIV+ MSM: Should we change our screening practice? Reiberger T. Division of Gastroenterology
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationGenotype 4. Sanaa Kamal, M.D., Ph.D. Professor. Ain Shams University, Cairo, Egypt Tufts School of Medicine
Optimal Therapy in Hepatitis C Genotype 4 Sanaa Kamal, M.D., Ph.D. Professor Ain Shams University, Cairo, Egypt Tufts School of Medicine Boston; USA HCV Genotype 4 True or False HCV-G4 is limited to Africa
More informationChronic viral hepatitis and liver disease in Belgium Pierre Deltenre
Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural
More information